| Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (NCT05381948) | EyePoint Pharmaceuticals, Inc. | 2022-06-30 |
| Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD (NCT04932980) | Berner Augenklinik | 2022-05-09 |
| Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration (NCT04919096) | Clover Biopharmaceuticals AUS Pty | 2022-04-01 |
| A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD) (NCT07389577) | Jecho Biopharmaceuticals Co., Ltd. | 2022-03-01 |
| Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (NCT05407636) | AbbVie | 2022-01-13 |
| A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) (NCT04964089) | Kodiak Sciences Inc | 2021-06-23 |
| Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD (NCT04884399) | Shanghai Biomabs Pharmaceutical Co., Ltd. | 2021-06-03 |
| A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD (NCT05297292) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2021-05-07 |
| RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD) (NCT04832724) | AbbVie | 2021-02-22 |
| First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD) (NCT04747197) | EyePoint Pharmaceuticals, Inc. | 2021-01-20 |
| Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD (NCT04704921) | AbbVie | 2020-12-29 |
| Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT] (NCT04645212) | Adverum Biotechnologies, Inc. | 2020-12-14 |
| Effectiveness of Anti-VEGF Treatments in Wet AMD in Active Smokers (NCT04685369) | Brugmann University Hospital | 2020-11-10 |
| MMP-9 Inhibition for Recalcitrant Wet AMD (NCT04504123) | University of Iowa | 2020-11-04 |
| A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration (NCT04594681) | Kyowa Kirin Co., Ltd. | 2020-09-16 |
| Clinical Study on the Efficacy and Safety of BAT5906 Injection (NCT05141994) | Bio-Thera Solutions | 2020-08-26 |
| A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD) (NCT04480463) | Sam Chun Dang Pharm. Co. Ltd. | 2020-08-13 |
| A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD) (NCT05345236) | Qilu Pharmaceutical Co., Ltd. | 2019-08-19 |
| Treat and Extend Analysis Trial With Aflibercept in Wet-AMD (NCT04113538) | Michel Giunta | 2019-07-24 |
| Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice (NCT03290794) | Bayer | 2019-02-14 |
| Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO (NCT03790852) | Kodiak Sciences Inc | 2018-12-26 |
| ADVM-022 Intravitreal Gene Therapy for Wet AMD (NCT03748784) | Adverum Biotechnologies, Inc. | 2018-11-14 |
| The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD) (NCT04468997) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2018-11-12 |
| AAVCAGsCD59 for the Treatment of Wet AMD (NCT03585556) | Janssen Research & Development, LLC | 2018-09-13 |
| Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration (NCT03558074) | Alkahest, Inc. | 2018-04-20 |
| Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration (NCT03558061) | Alkahest, Inc. | 2018-04-04 |
| Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD (NCT03312283) | Qilu Pharmaceutical Co., Ltd. | 2017-12-20 |
| Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients (NCT03382587) | Bayer | 2017-12-05 |
| Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial (NCT03066258) | REGENXBIO Inc. | 2017-03-29 |
| Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration (NCT02257632) | Novartis Pharmaceuticals | 2015-04-08 |
| Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye (NCT01986907) | Novartis Pharmaceuticals | 2014-03-04 |
| A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics (NCT02005133) | Novartis Pharmaceuticals | 2013-11-01 |
| Time to Treatment Utilizing a Tele-Retinal Referral System for wAMD and DME: A Pilot Study (NCT01899963) | McMaster University | 2013-11-01 |
| Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV) (NCT01339949) | Oraya Therapeutics, Inc. | 2011-06-01 |
| Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (NCT01318941) | Novartis Pharmaceuticals | 2011-03-01 |
| Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration (NCT01086761) | Allergan | 2010-03-01 |
| INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD (NCT01016873) | Oraya Therapeutics, Inc. | 2009-11-01 |
| Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (NCT01217762) | Oraya Therapeutics, Inc. | 2008-07-01 |
| A Study to Evaluate the Neovista Ophthalmic System for the Treatment of Subfoveal CNV in Patients With AMD That Have Failed Primary Anti-VEGF Therapy (NCT00679445) | NeoVista | 2007-12-01 |
| Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration (NCT00503022) | Novartis | 2006-07-01 |
| Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD) (NCT00138632) | Novartis | 2005-09-01 |
| A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration (NCT00139282) | Genaera Corporation | 2005-06-01 |
| Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration (NCT02036723) | Biocad | |